Both Spero Therapeutics Inc. (NASDAQ:SPRO) and CRISPR Therapeutics AG (NASDAQ:CRSP) are Biotechnology companies, competing one another. We will compare their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Spero Therapeutics Inc.||11||-0.15||12.36M||-2.18||0.00|
|CRISPR Therapeutics AG||56||0.00||34.37M||-3.74||0.00|
In table 1 we can see Spero Therapeutics Inc. and CRISPR Therapeutics AG’s gross revenue, earnings per share and valuation.
Table 2 shows the return on equity, return on assets and net margins of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Spero Therapeutics Inc.||114,127,423.82%||-34.5%||-31.2%|
|CRISPR Therapeutics AG||61,805,430.68%||-50.9%||-39.8%|
Spero Therapeutics Inc.’s Current Ratio is 17.5 while its Quick Ratio is 17.5. On the competitive side is, CRISPR Therapeutics AG which has a 15.8 Current Ratio and a 15.8 Quick Ratio. Spero Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to CRISPR Therapeutics AG.
In next table is delivered Spero Therapeutics Inc. and CRISPR Therapeutics AG’s ratings and recommendations.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Spero Therapeutics Inc.||0||0||1||3.00|
|CRISPR Therapeutics AG||0||0||4||3.00|
Spero Therapeutics Inc. has a 193.13% upside potential and a consensus price target of $35. Competitively CRISPR Therapeutics AG has a consensus price target of $66.5, with potential downside of -8.11%. Based on the data delivered earlier, Spero Therapeutics Inc. is looking more favorable than CRISPR Therapeutics AG, analysts belief.
Institutional & Insider Ownership
Institutional investors owned 53.1% of Spero Therapeutics Inc. shares and 50% of CRISPR Therapeutics AG shares. Insiders owned roughly 23.71% of Spero Therapeutics Inc.’s shares. Insiders Comparatively, owned 2% of CRISPR Therapeutics AG shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Spero Therapeutics Inc.||-0.95%||-11.87%||-4.77%||9.14%||-5.63%||68.94%|
|CRISPR Therapeutics AG||3.15%||6.25%||30.58%||57.23%||7.51%||77.42%|
For the past year Spero Therapeutics Inc. has weaker performance than CRISPR Therapeutics AG
Spero Therapeutics Inc. beats on 7 of the 11 factors CRISPR Therapeutics AG.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.